The Effects of Silibinin Combined With EGFR‐TKIs in the Treatment of NSCLC
ABSTRACT Background Currently, the most effective oral targeted therapies for NSCLC in clinical practice are EGFR‐TKIs. However, acquired drug resistance often leads to tumor progression and recurrence. EGFR overexpression and activation of its downstream pathways are primary contributors to both mu...
-д хадгалсан:
| Үндсэн зохиолч: | |
|---|---|
| Формат: | Artigo |
| Хэл сонгох: | Inglês |
| Хэвлэсэн: |
Wiley
2025-02-01
|
| Цуврал: | Cancer Medicine |
| Нөхцлүүд: | |
| Онлайн хандалт: | https://doi.org/10.1002/cam4.70643 |
| Шошгууд: |
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|